Risk Evaluation and Mitigation Strategies (REMS)
and Opioid Analgesics Webinar

The Center for Drug Evaluation and Research (CDER) and Office of Special Health Issues (OSHI) developed the following Webinar to better inform stakeholders about general issues related to Risk Evaluation and Mitigation Strategies (REMS) and specific issues related to REMS for certain opioid analgesics. 

Part I –Introduction (8:21 minutes)
Douglas C. Throckmorton, M.D.
Deputy Director (CDER)
https://webmeeting.nih.gov/p53364025/

Part II – Opioid Analgesics (6:28 minutes)
Sharon Hertz, M.D., Deputy Division Director                                
Division of Anesthesia, Analgesia, and Rheumatology Products (CDER)
https://webmeeting.nih.gov/p59178873/

Part III – REMS (23:51 minutes)
John Jenkins, M.D.  
Director, Office of New Drugs (CDER)
https://webmeeting.nih.gov/p51598115/

Part IV – Next Steps (6:22 minutes)
John Jenkins, M.D.  
Director, Office of New Drugs (CDER)
https://webmeeting.nih.gov/p57998755/

PDF Version of Slides

• Part I - Introduction
• Part II - Opioid Analgesics
• Part III - REMS
• Part IV - Next Steps

Back to Top     Back to Opioids

PDF requires the free Adobe Acrobat Reader

Date created: April 27, 2009

CDER Home Page | CDER Site Info | Contact CDER | What's New @ CDER
FDA Home Page | Search FDA Site | FDA A-Z Index | Contact FDA | Privacy | Accessibility | HHS Home Page

FDA/Center for Drug Evaluation and Research